Ortanol 20 Plus (Omeprazole)

Omeprazole, the active ingredient in Ortalan 20 Plus, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Ortalan 20 Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to manage conditions driven by excess stomach acid. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with the condition.

Adverse reactions to omeprazole are generally mild but can vary in frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional upset stomach. - Abdominal pain: mild cramping. - Flatulence: increased intestinal gas. - Constipation: occasional difficulty passing stools.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome: rare severe skin reaction. - Acute interstitial nephritis: kidney inflammation. - Hepatic injury: elevated liver enzymes or hepatitis. - Fracture risk: possible reduction in bone mineral density with long‑term use.

Before initiating omeprazole therapy, consider the following safety measures: - Assess renal function: adjust use in severe impairment. - Review hepatic status: use with caution in liver disease. - Evaluate need for long‑term therapy: weigh benefits against potential bone density loss. - Monitor electrolytes: especially magnesium during prolonged treatment. - Consider drug‑induced nutrient absorption issues: vitamin B12 and iron may be affected. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased antiviral exposure, compromising HIV therapy. - Dasatinib: lowered plasma concentrations, reducing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Phenytoin: may reduce serum levels, risking seizure control. - Methotrexate: increased exposure, especially at high doses. - Digoxin: modest rise in serum concentration, watch for toxicity.